Clinical trial
Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer
NCT00472693
Study timeline
Study start (unknown)2007-05-01Date precision: month
Registry last updated2020-04-09
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Cancerunresolved
Interventions
Sponsors & collaborators
Abramson Cancer Center at Penn Medicinelead sponsor
Genentech, Inc.collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00472693 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.